Evaluation of Safety and Pharmacokinetics of Single Doses of VBY-376 in Healthy Adults

• Status: Completed
• Trial end date: 2008-02-01
• Target enrollment: 0
• Participant gender: All

Summary

The study will evaluate the safety and pharmacokinetics of single doses of VBY-376 in healthy subjects.

• Phase: Phase 1
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Virobay Inc.

Criteria

Inclusion Criteria:

• males and females between 18 and 45 years of age

• screening body mass index between 20 and 29 kg/m2

• in good health with no clinically significant medical conditions

• able to comprehend and willing to sign an informed consent

Exclusion Criteria:

• history of renal, hepatic impairment, stomach or intestinal surgery or resection, malabsorption syndrome

• anemia or blood donation within 8 weeks of check-in

• plasma donation within 4 weeks of check-in

• history of alcoholism or drug addiction within 1 year prior to check-in

• use of drugs of abuse

• no tobacco-containing products within 6 months of study

• participation of any clinical trial within 30 days

• history or presence of abnormal ECG

• no prescription or over-the-counter medications within 14 days of study and during the study

• history of Gilbert's syndrome